keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis in CKD

keyword
https://www.readbyqxmd.com/read/28992067/the-uremic-toxin-indoxyl-sulfate-interferes-with-iron-metabolism-by-regulating-hepcidin-in-chronic-kidney-disease
#1
Hirofumi Hamano, Yasumasa Ikeda, Hiroaki Watanabe, Yuya Horinouchi, Yuki Izawa-Ishizawa, Masaki Imanishi, Yoshito Zamami, Kenshi Takechi, Licht Miyamoto, Keisuke Ishizawa, Koichiro Tsuchiya, Toshiaki Tamaki
Background: Hepcidin secreted by hepatocytes is a key regulator of iron metabolism throughout the body. Hepcidin concentrations are increased in chronic kidney disease (CKD), contributing to abnormalities in iron metabolism. Levels of indoxyl sulfate (IS), a uremic toxin, are also elevated in CKD. However, the effect of IS accumulation on iron metabolism remains unclear. Methods: We used HepG2 cells to determine the mechanism by which IS regulates hepcidin concentrations...
August 23, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28954928/human-pluripotent-stem-cell-derived-erythropoietin-producing-cells-ameliorate-renal-anemia-in-mice
#2
Hirofumi Hitomi, Tomoko Kasahara, Naoko Katagiri, Azusa Hoshina, Shin-Ichi Mae, Maki Kotaka, Takafumi Toyohara, Asadur Rahman, Daisuke Nakano, Akira Niwa, Megumu K Saito, Tatsutoshi Nakahata, Akira Nishiyama, Kenji Osafune
The production of erythropoietin (EPO) by the kidneys, a principal hormone for the hematopoietic system, is reduced in patients with chronic kidney disease (CKD), eventually resulting in severe anemia. Although recombinant human EPO treatment improves anemia in patients with CKD, returning to full red blood cell production without fluctuations does not always occur. We established a method to generate EPO-producing cells from human induced pluripotent stem cells (hiPSCs) by modifying previously reported hepatic differentiation protocols...
September 27, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28939957/effect-of-hepatitis-c-treatment-with-ombitasvir-paritaprevir-r%C3%A2-%C3%A2-dasabuvir-on-renal-cardiovascular-and-metabolic-extrahepatic-manifestations-a-post-hoc-analysis-of-phase-3-clinical-trials
#3
Darshan A Mehta, Eric Cohen, Mariem Charafeddine, Daniel E Cohen, Yanjun Bao, Yuri Sanchez Gonzalez, Tram T Tran
INTRODUCTION: We analyzed phase 3 trial data of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) ± ribavirin (RBV) in genotype 1 chronic hepatitis C patients to investigate the impact of 3D ± RBV on renal, cardiovascular and metabolic extrahepatic manifestations (EHMs), including persistency 52 weeks post treatment and differential impact by EHM disease severity. METHODS: Estimated glomerular filtration rate (eGFR), fasting triglyceride and fasting glucose values from clinical trials were used to assess renal, cardiovascular and metabolic EHMs, respectively...
September 22, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28927317/worse-renal-outcome-of-subclass-iv-g-lupus-nephritis-patients-over-iv-s
#4
E J Duque de Sá Carneiro Filho, L B Jorge, L Testagrossa, C Bitencourt, L Yu, V Woronik
Background International Society of Nephrology/ Renal Pathology Society (ISN/RPS) consensus on the classification of lupus nephritis (LN) subdivided class IV into diffuse segmental (IV-S) and diffuse global (IV-G). Nephrologists and nephropathologists believe that this subclassification would be clinically relevant based on hypothetical distinct immunopathogenesis of those subclasses guiding therapy as well as judging prognosis. Methods All adult patients with a renal biopsy-confirmed diagnosis of LN class IV undergoing regular follow-up in the Nephrology Division between January 2004 and December 2014 were enrolled excluding those with diabetes, hepatitis B, hepatitis C, HIV as well as those with insufficient clinical and hystopathological data...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28922657/methods-employed-in-cytofluorometric-assessment-of-eryptosis-the-suicidal-erythrocyte-death
#5
Mohamed Jemaà, Myriam Fezai, Rosi Bissinger, Florian Lang
Suicidal erythrocyte death or eryptosis contributes to or even accounts for anemia in a wide variety of clinical conditions, such as iron deficiency, dehydration, hyperphosphatemia, vitamin D excess, chronic kidney disease (CKD), hemolytic-uremic syndrome, diabetes, hepatic failure, malignancy, arteriitis, sepsis, fever, malaria, sickle-cell disease, beta-thalassemia, Hb-C and G6PD-deficiency, Wilsons disease, as well as advanced age. Moreover, eryptosis is triggered by a myriad of xenobiotics and endogenous substances including cytotoxic drugs and uremic toxins...
September 1, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28903508/effect-of-paritaprevir-ritonavir-ombitasvir-dasabuvir-and-ledipasvir-sofosbuvir-regimens-on-survival-compared-with-untreated-hepatitis-c-virus-infected-persons-results-from-erchives
#6
Adeel Ajwad Butt, Peng Yan, Tracey G Simon, Abdul-Badi Abou-Samra
Background: Interferon-based regimens are associated with a substantial survival benefit for persons infected with hepatitis C virus (HCV). Survival data with direct-acting antiviral agents are not available. We conducted this study to quantify the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality. Methods: In the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a well-established national cohort of HCV-infected Veterans, we identified HCV-infected persons initiated on PrOD or LDV/SOF, excluding those with human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or missing HCV RNA or FIB-4 scores...
September 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28902234/monitoring-of-post-vaccination-anti-hbs-titles-vaccine-in-children-and-adolescents-in-the-pre-dialysis-of-chronic-kidney-disease
#7
Nathália Cristina Pereira da Costa, Mônica Ribeiro Canhestro, Cristina Maria Bouissou Morais Soares, Juliana Scudilio Rodrigues
Introduction: Bacterial or viral diseases are one of the major causes of death in patients with chronic kidney disease (CKD). These patients show a quantitative reduction of levels of antibodies over time. Among the infectious diseases that affect CKD patients, stands out hepatitis B (HB). Immunization and control of antibodies levels against the hepatitis B surface antigen (anti-HBs) are ways to prevent the HB infection in this population. Patients with anti-HBs levels ≥10 IU/ml are considered adequate responders, whereas those with anti-HBs levels ≥ 100 IU/ml are considered excellent responders...
August 28, 2017: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/28882857/effect-of-sofosbuvir-based-hepatitis-c-virus-therapy-on-kidney-function-in-patients-with-ckd
#8
Meghan E Sise, Elke Backman, Guillermo A Ortiz, Gregory L Hundemer, Nneka N Ufere, Donald F Chute, Joseph Brancale, Dihua Xu, Jessica Wisocky, Ming V Lin, Arthur Y Kim, Ravi Thadhani, Raymond T Chung
BACKGROUND AND OBJECTIVES: Hepatitis C virus infection is common in patients with CKD and leads to accelerated progression to ESRD. Sofosbuvir is a potent direct-acting antiviral therapy against hepatitis C virus; however, there are concerns about its safety in patients with CKD. The objective of our study was to determine the safety and efficacy of sofosbuvir in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied a retrospective observational cohort of patients with CKD defined by eGFR<60 ml/min per 1...
October 6, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28882856/contemporary-management-of-hepatitis-c-in-patients-with-ckd
#9
EDITORIAL
Richard J Johnson, Michiko Shimada
No abstract text is available yet for this article.
October 6, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28873225/chronic-hepatitis-c-increases-the-risk-of-chronic-kidney-disease-ckd-while-effective-hcv-treatment-decreases-the-incidence-of-ckd
#10
Haesuk Park, Chao Chen, Wei Wang, Linda Henry, Robert L Cook, David R Nelson
We aimed to assess the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV) infected patients and the incidence reduction of CKD after receipt of HCV treatment. We also evaluated the risk of membranoproliferative glomerulonephritis (MPGN) and cryoglobulinemia in chronic HCV patients. A retrospective cohort analysis of the Truven Health MarketScan Database (2008-2015) in the United States was conducted. In a cohort of 56,448 HCV-infected patients and propensity score (1:3) matched 169,344 non-HCV patients, we examined the association of HCV infection with the incidence of CKD...
September 5, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28843775/parathyroid-hormone-contributes-to-the-down-regulation-of-cytochrome-p450-3a-through-the-camp-pi3k-pkc-pka-nf-%C3%AE%C2%BAb-signaling-pathway-in-secondary-hyperparathyroidism
#11
Hiroshi Watanabe, Ryusei Sugimoto, Komei Ikegami, Yuki Enoki, Tadashi Imafuku, Rui Fujimura, Jing Bi, Kento Nishida, Yoshiaki Sakaguchi, Michiya Murata, Hitoshi Maeda, Kenshiro Hirata, Sachiko Jingami, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, Toru Maruyama
Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models...
August 24, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28827512/efficacy-and-safety-of-sofosbuvir-based-regimens-for-treatment-in-chronic-hepatitis-c-genotype-1-patients-with-moderately-impaired-renal-function
#12
Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A Kozarek, Asma Siddique
Background/Aims: Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates, however there is insufficient data regarding its use in patients with CKD. We evaluated SOF in patients with hepatitis C genotype 1 (G1) and moderately impaired renal function. Methods: We retrospectively reviewed all patients treated with a SOF-based regimen from December 2013 through September 2015 at Virginia Mason Medical Center...
August 22, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28814273/add-on-neurological-benefits-of-antiviral-therapy-in-hcv-patients-with-chronic-kidney-disease-a-nationwide-cohort-study
#13
Ming-Shyan Lin, Tien-Hsing Chen, Wey-Yil Lin, Chi-Hung Liu, Yung-Yu Hsieh, Wen-Nan Chiu, Chih-Hsiang Chang, Mei-Yen Chen, Chang-Min Chung, Yu-Sheng Lin
BACKGROUND: Hepatitis C virus (HCV)-infected patients with chronic kidney disease (CKD) have rarely been studied because they rarely accept interferon-based therapy (IBT) and have been difficult to follow up. We investigated long-term outcomes of IBT on the population. METHODS: This population-based cohort study used the Taiwan National Health Insurance Research Database as its data source. HCV patients diagnosed with CKD between Jan. 1, 2003, and Dec. 31, 2013, were selected...
August 16, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28793953/the-spectrum-of-biopsy-proven-secondary-glomerular-diseases-a-cross-sectional-study-in-china%C3%A2
#14
Ping Wang, Lijun Tang, Jing Yao, Hong Su, Yipeng Liu, Xianglei Kong, Wenbin Li, Meiyu Cui, Qing Sun, Junhui Zhen, Dongmei Xu
AIMS: The distribution of the spectrum of chronic kidney disease (CKD) has been found to vary with time. Limited information is available regarding the changing spectrum of secondary glomerular diseases (SGDs). To further investigate changes in the spectrum of SGDs, we performed a cross-sectional study. METHODS: From June 2010 to May 2015, 5,935 patients from 37 hospitals in Shandong Province were involved in this study. The study was divided into five periods according to 1-year intervals...
August 10, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28757867/factors-related-to-significant-improvement-of-estimated-glomerular-filtration-rates-in-chronic-hepatitis-b-patients-receiving-telbivudine-therapy
#15
Te-Fu Lin, Ping-I Hsu, Kung-Hung Lin, Feng-Woei Tsay, Tzung-Jiun Tsai, Yan-Hua Chen, Hsien-Chung Yu
BACKGROUND AND AIM: The improvement of estimated glomerular filtration rates (eGFRs) in chronic hepatitis B (CHB) patients receiving telbivudine therapy is well known. The aim of this study was to clarify the kinetics of eGFRs and to identify the significant factors related to the improvement of eGFRs in telbivudine-treated CHB patients in a real-world setting. METHODS: Serial eGFRs were calculated every 3 months using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28748890/prevalence-of-hepatitis-b-core-antibodies-with-negative-hepatitis-b-surface-antigen-in-dialysis-and-chronic-kidney-disease-patients
#16
Nauman Tarif, Muhammad Mohsin Riaz, Omer Sabir, Rizwan Akhter, Kashif Rafique, Nabiha Rizvi
Occult hepatitis B infection (OBI) is a potential cause of infection transmission in patients with chronic kidney disease (CKD) and dialysis-dependant patients. It is liable to be missed since the marker for OBI, hepatitis B core antibody (HBcAb), is not done routinely. We carried out a study to assess the prevalence of OBI in CKD Stage II-V or requiring renal replacement therapy. It was a cross-sectional study carried out at Fatima Memorial Hospital, Lahore, from May 2104 to May 2015. A total of 188 patients were included in this study, 124 were dialysis dependent and 64 had acute or CKD Stage II-V...
July 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28741977/reduction-in-the-presence-of-cryoglobulins-over-time-in-the-hemodialysis-treatment
#17
Tainá Mosca, Simone Sanches Arcuri, Luiz Antônio Miorin, Andrelita de Oliveira Cristiano, Yvoty Alves Dos Santos Sens, Wilma Carvalho Neves Forte
BACKGROUND: The presence of cryoglobulins in patients with chronic kidney disease (CKD) on hemodialysis is well described. However, the generation of cryoglobulins during the dialysis treatment has yet to be established. The aim of the present study was to determine the presence of serum cryoglobulins over time in the dialysis treatment in patients with CKD not infected with hepatitis C virus (HCV). METHOD: Peripheral blood samples were collected at the beginning of dialysis treatment and at 30, 60, 90 and 120 days afterwards...
November 2017: Renal Failure
https://www.readbyqxmd.com/read/28740594/opportunities-for-treatment-of-the-hepatitis-c-virus-infected-patient-with-chronic-kidney-disease
#18
REVIEW
Marco Ladino, Fernando Pedraza, David Roth
The prevalence of hepatitis C virus (HCV) infection amongst patients with chronic kidney disease (CKD) and end-stage renal disease exceeds that of the general population. In addition to predisposing to the development of cirrhosis and hepatocellular carcinoma, infection with HCV has been associated with extra-hepatic complications including CKD, proteinuria, glomerulonephritis, cryoglobulinemia, increased cardiovascular risk, insulin resistance, and lymphoma. With these associated morbidities, infection with HCV is not unexpectedly accompanied by an increase in mortality in the general population as well as in patients with kidney disease...
July 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28738449/pbpk-modeling-of-the-effect-of-reduced-kidney-function-on-the-pharmacokinetics-of-drugs-excreted-renally-by-organic-anion-transporters
#19
C-H Hsueh, V Hsu, P Zhao, L Zhang, K M Giacomini, S-M Huang
Altered pharmacokinetics (PK) in subjects with chronic kidney disease (CKD) may lead to dosing adjustment of certain drugs in subjects with CKD. It can be valuable to quantitatively predict PK in CKD for the management of drug dosing in these subjects. We developed physiologically based pharmacokinetic (PBPK) models of seven renally eliminated drugs: adefovir, avibactam, entecavir, famotidine, ganciclovir, oseltamivir carboxylate, and sitagliptin. These drugs are all substrates of renal organic anion transporters (OATs)...
July 24, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28721452/enhanced-efficacy-of-radiofrequency-ablation-for-hepatocellular-carcinoma-using-a-novel-vascular-disrupting-agent-ckd-516
#20
Su Jung Ham, YoonSeok Choi, Seul-I Lee, Jinil Kim, Young Il Kim, Jin Wook Chung, Kyung Won Kim
BACKGROUND: CKD-516 is a novel vascular disrupting agent that shuts down intratumoral blood flow. We therefore hypothesized that concomitant administration of CKD-516 would enhance the therapeutic efficacy of radiofrequency ablation (RFA) by reducing heat sink effects. We assessed the effects of the combination of CKD-516 and RFA in a rat orthotopic hepatocellular carcinoma (HCC) model. METHODS: Rat HCC cells (N1-S1) were engrafted into the hepatic lobe of Sprague-Dawley (SD) rats...
July 18, 2017: Hepatology International
keyword
keyword
26434
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"